AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement With VisionPlus Corp. for TearScan(R) Lactoferrin and IgE Diagnostic Tests in South Korea

AXIM Biotechnologies, Inc. (OTC:AXIM), a pioneer in rapid ocular diagnostics, has announced an exclusive distribution agreement with VisionPlus Corp. to market and distribute its innovative TearScan® diagnostic tests in South Korea. The agreement, effective immediately, covers the TearScan® Lactoferrin Test, designed for detecting aqueous-deficient dry eye (ADDE), and the TearScan® IgE Test for identifying ocular allergies. VisionPlus will bring these tests to market in South Korea, leveraging its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers.

Under the terms of the agreement, VisionPlus will oversee local compliance, regulatory coordination, and the commercialization of the diagnostic tests, while AXIM retains control over manufacturing, intellectual property, and provides ongoing regulatory and technical support. The initial agreement spans one year, with potential automatic renewals for up to four additional years, contingent upon achieving sales milestones.

Catalina Valencia, President of AXIM, emphasized VisionPlus’s suitability as a partner, highlighting their commitment to ocular health and their infrastructure to facilitate the introduction of AXIM's TearScan® platform. This collaboration aims to provide clinicians with efficient, quantitative tear diagnostics that can enhance personal care for patients suffering from dry eye conditions.

Jerry Park, President of VisionPlus, echoed this sentiment, noting that the partnership is a crucial step toward establishing a comprehensive diagnostic and treatment ecosystem for Dry Eye Disease in South Korea. AXIM’s TearScan® diagnostics offer rapid, laboratory-grade tear biomarker analysis, crucial for differentiating between various types of dry eye conditions, thereby improving patient care and therapeutic effectiveness.

For additional details about AXIM Biotechnologies, visit www.aximbiotech.com.

AXIM Biotechnologies, Inc. (OTC:AXIM) recently announced an exclusive distribution agreement with VisionPlus Corp. to market its TearScan® Lactoferrin and IgE diagnostic tests in South Korea. This partnership positions AXIM favorably within the growing ocular diagnostics market, particularly given the rising prevalence of dry eye disease (DED) and ocular allergies attributed to increased digital device usage and environmental factors.

Investors should consider several key aspects of this development. Firstly, the exclusive rights granted to VisionPlus to distribute these tests enhance AXIM’s geographic reach and market penetration without incurring excessive operational costs. VisionPlus’s established network of ophthalmology clinics and specialty Dry Eye Centers provides a robust channel for introducing AXIM’s diagnostic tools, suggesting potential for rapid adoption. The collaboration also includes support for Korean regulatory compliance, which is vital for successful market entry and sustainability.

The initial one-year term, with automatic renewals linked to sales milestones, aligns AXIM's growth with performance metrics. Meeting these milestones ensures ongoing partnership viability and financial stability in a high-demand market. Importantly, AXIM retains control of manufacturing and intellectual property, allowing for continuous innovation and quality assurance—a significant competitive advantage.

The TearScan® platform’s ability to deliver rapid, accurate diagnostics in a point-of-care setting represents a meaningful evolution in eye care, potentially unlocking significant market share in DED and allergic conjunctivitis treatment. As healthcare professionals increasingly seek quick, reliable testing options, AXIM's products could see exponential growth in utilization.

Investors considering AXIM may find this partnership a strong indicator of future performance and market relevance. However, risks remain, including reliance on successful regulatory approvals and market acceptance, so potential investors should monitor AXIM's progress closely. Overall, this agreement may signal a turning point for AXIM as it expands its footprint in a lucrative and necessary health sector.